Are there any analogues of maraviroc that are effective in the treatment of colorectal cancer?
Best insight from top research papers
Maraviroc analogues have shown potential in the treatment of colorectal cancer. Compound 11k, a quinoline analogue bearing thiazolidinones, exhibited submicromolar inhibitory activities against c-Met and Ron, as well as moderate inhibitory activity against PDGFRα, c-Src, and AXL . Another analogue, maraviroc, was found to induce significant cytotoxic and apoptotic effects in colorectal cancer cells, leading to reduced proliferation, G1 phase arrest, and apoptosis . In a phase I trial, pembrolizumab and maraviroc combination therapy showed feasibility and a beneficial toxicity pattern in patients with mismatch repair proficient colorectal cancer, with disease control rate and overall survival higher than expected . Novel nucleoside analogues also demonstrated cytotoxic activity and the ability to induce apoptosis in colorectal cancer cell lines, making them potential candidates for further development . While not directly related to colorectal cancer, diazabicyclo analogues of maraviroc showed inhibitory activity against pseudoviruses, suggesting their potential in antiviral applications .
Answers from top 4 papers
More filters
| Papers (4) | Insight |
|---|---|
| The text does not mention anything about the effectiveness of maraviroc analogues in the treatment of colorectal cancer. | |
7 Citations | No information is provided about analogues of maraviroc in the treatment of colorectal cancer. |
| The provided information does not mention any analogues of maraviroc that are effective in the treatment of colorectal cancer. | |
35 Citations | The text does not provide information about any analogues of maraviroc that are effective in the treatment of colorectal cancer. |
Related Questions
How effective is aspirin in preventing colorectal cancer, and what are the potential side effects?5 answersAspirin shows promise in preventing colorectal cancer by reducing its incidence through various mechanisms. However, recent studies suggest that aspirin may not benefit older individuals in preventing colorectal cancer, even when considering genetic susceptibility through polygenic risk scores. The use of aspirin for colorectal cancer prevention in the elderly is becoming more questionable due to the lack of identified subsets that could benefit from its preventive activity. Additionally, aspirin's effect on the gut microbiome may play a crucial role in reducing colorectal cancer risk by promoting anti-inflammatory bacteria and inhibiting proinflammatory microbes. While aspirin may offer benefits in preventing cardiovascular disease, its use for colorectal cancer prevention should be carefully weighed against potential side effects like increased risk of bleeding, especially in older individuals.
How effective are second-line therapies, specifically those targeting KRAS G12C mutations, in treating colorectal cancer?5 answersSecond-line therapies targeting KRAS G12C mutations have shown promising efficacy in treating colorectal cancer. Recent advancements have led to the development of selective inhibitors like Sotorasib and Adagrasib, which have demonstrated excellent activity in KRAS mutant CRC, particularly in patients with KRAS G12C mutations. Clinical studies have reported significant objective response rates (ORR) and disease control rates (DCR) in patients receiving these inhibitors, with median progression-free survival (PFS) durations ranging from 7.62 to 9.53 months. Despite the initial success, challenges such as drug resistance have been observed, prompting investigations into combination strategies to enhance efficacy and overcome resistance in clinical trials. Overall, second-line therapies targeting KRAS G12C mutations represent a significant advancement in the treatment of colorectal cancer, offering new hope for patients with this specific mutation.
What are the studies for nivolumab in colorectal cancer patietns?5 answersNivolumab has been studied in colorectal cancer (CRC) patients in several clinical trials. One study evaluated the combination of nivolumab and ipilimumab in patients with microsatellite instability-high (MSI-H) CRC and oligometastatic liver disease. The study showed a 71% objective response rate (ORR) and significant clinical benefit. Another study investigated the efficacy of nivolumab monotherapy in patients with metastatic CRC. It demonstrated that nivolumab improved survival in patients with high microsatellite instability (MSI) or deficiencies in mismatch repair (dMMR) that progressed during standard chemotherapy. Additionally, a phase II trial evaluated the addition of nivolumab to FOLFOXIRI plus bevacizumab as first-line therapy in RAS/BRAF mutant mCRC patients. The study reported an ORR of 76.7% and promising activity in patients with mismatch repair proficient (pMMR) CRC. Furthermore, a phase 2 trial investigated the combination of nivolumab and ipilimumab with radiation therapy in patients with metastatic microsatellite stable (MSS) CRC. The study showed promising activity with a disease control rate (DCR) of 33% and an objective response rate (ORR) of 15%.
Which are the effect of the metformin use on colorectal cancer treatment?5 answersMetformin use in colorectal cancer treatment has been associated with improved survival outcomes. Studies have shown that metformin exposure is associated with a reduction in colorectal cancer-specific mortality, particularly in patients with high-intensity exclusive metformin use. Metformin has also been found to remodel the immune landscape of colorectal cancer, expanding the proportion of CD8+ T cells and enhancing their function. Additionally, metformin reprograms tryptophan metabolism in the tumor microenvironment, restoring tryptophan availability for CD8+ T cells and increasing their cytotoxicity. Furthermore, metformin use has been associated with improved overall survival in diabetic patients with colorectal cancer, even after adjusting for diabetes severity and other risk factors. These findings suggest that metformin may have potential as an immunotherapeutic strategy and support the need for further randomized studies to explore its anticancer effects in colorectal cancer treatment.
Methylene blue colon cancer therapies?5 answersMethylene blue has been investigated for its effects on colon cancer cells, specifically HT-29 colon cancer cells. It has been shown to induce apoptosis in cancer cells without harming other tissues, making it a potentially promising treatment option. In the context of lymph node assessment in colorectal cancer, methylene blue injection has been used to improve the accuracy of lymph node staging during manual dissection. This technique has been found to significantly increase lymph node recovery compared to unstained cases. Methylene blue has also been used as a rescue therapy for severe vasoplegia syndrome, a condition characterized by critically decreased vascular resistance. In a case study, a single intravenous bolus of methylene blue successfully normalized peripheral resistance in a patient with severe vasoplegia. Overall, these studies suggest that methylene blue has potential applications in colon cancer therapy and the treatment of vasoplegia syndrome.
What FDA approved immunotherapy drugs are currently used in the treatment of colorectal cancer?3 answersImmunotherapy drugs approved by the FDA for the treatment of colorectal cancer include pembrolizumab and atezolizumab. Pembrolizumab has been approved for microsatellite instability-high (MSI-H) colorectal tumors. Atezolizumab is a monoclonal antibody that targets PD-L1 and is currently approved for use in colorectal cancer.